Skip to main content
SpringerLink
Log in

Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We have investigated the effects of transient Bcl-2 down-regulation induced by the Bcl-2 antisense oligodeoxynucleotide (ODN) G3139 (Genta Incorporated) in high Bcl-2 protein expressing, estrogen receptor (ER) positive MCF-7 and low Bcl-2 expressing, ER negative MDA435/LCC6 human breast cancer cells. Treatment with Bcl-2 antisense ODN in vitro caused > 80% reduction of Bcl-2 protein levels in a sequence specific manner for both cell lines. Maximum mRNA reduction was achieved within 24 h of the first antisense ODN exposure whereas full protein down-regulation required antisense exposure over 48 h. This Bcl-2 reduction was associated with 80–95% loss of viable cells compared to untreated cells. Similar cytotoxic effects were observed in both cell lines despite a nine-fold intrinsic difference in Bcl-2 protein expression suggesting that the relative degree of down-regulation of Bcl-2 is more important than the absolute reduction. Cell death associated with G3139 exposure exhibited properties indicative of apoptosis such as mitochondrial membrane depolarization and caspase activation. Combined treatment with G3139 and cytotoxic agents resulted in additive cytotoxicity in both cell lines. However, under most conditions studied, the direct cytotoxic activity of G3139 antisense was not synergistic with the cytotoxic agents. These results suggest that while Bcl-2 clearly constitutes an attractive therapeutic target due to its role in regulating apoptosis in breast cancer cells, additional mechanisms are important in the control of apoptosis arising from exposure to anticancer agents in vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reed JC: Prevention of apoptosis as a mechanism of drug resistance. Hem Onc Clinics North Am 9: 451–473, 1995

    Google Scholar 

  2. Teixera C, Reed JC, Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902–3907, 1995

    PubMed  Google Scholar 

  3. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440–442, 1988

    Article  PubMed  Google Scholar 

  4. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G: Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57: 62–67, 1997

    PubMed  Google Scholar 

  5. Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoid and multiple chemotherapeutic drugs. Cancer Res 52: 5407

  6. Burkhard J, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 4: 232–234, 1998

    PubMed  Google Scholar 

  7. Ziegler A, Luedke GH, Fabbro D, Ahmann KH, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89: 1027–1036, 1997

    Article  PubMed  Google Scholar 

  8. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotide suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049–3055, 1994

    PubMed  Google Scholar 

  9. Yang D, Ling Y, Almazan M, Guo R, Murray A, Brown B, Lippman ME: Tumor regression of human breast carcinoma by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs (Abstract). Proc Amer Assoc Cancer Res 40: 4814, 1999

    Google Scholar 

  10. Tolcher A, Miyake H, Gleave ME: Downregulation of Bcl-2 expression by antisense oligonucleotide (AS-ODN) treatment enhances mitoxantrone cytotoxicity in the androgen dependent Shionogi tumor model (Abstract). Proc Amer Assoc Cancer Res 40: 3198, 1999

    Google Scholar 

  11. Reed JC, Stein C, Subasinghe C, Haldan S, Croce CM, Yum S, Cohen J: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50: 6565–6570, 1990

    PubMed  Google Scholar 

  12. Kitada S, Miyashita T, Tanaka S, Reed JC: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 3: 157–169, 1993

    PubMed  Google Scholar 

  13. Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 56: 2033–2038, 1996

    PubMed  Google Scholar 

  14. Bedner B, Li X, Gorczyca W, Melamed MR, Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry. Cytometry 35: 181–195, 1999

    PubMed  Google Scholar 

  15. Memon SA, Moreno MB, Petrak D, Zacharchuk CM: Bcl-2 blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T-cell hybridoma. J Immunol 155: 4644–4652, 1995

    PubMed  Google Scholar 

  16. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA: Synergistic cytoxicity of bcl-2 antisense oligodeoxynucleotide and etoposide, doxorubicin and cisplatin in small-cell lung cancer cell lines. Br J Cancer 78: 1035–1042, 1998

    PubMed  Google Scholar 

  17. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisensemediated reduction of bcl-2 gene expression. Antisense Res Dev 4: 71–79, 1994

    PubMed  Google Scholar 

  18. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137–1141, 1997

    Article  PubMed  Google Scholar 

  19. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354–360, 1995

    PubMed  Google Scholar 

  20. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604–1610, 1996

    PubMed  Google Scholar 

  21. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hollenstein U, Lucas T, Eichler H-GG, Wolff K, Pehamberger H: A Phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (Genta) as a chemosensitizer in patients with advanced malignant melanoma (Abstract). Proc Amer Assoc Clin Oncol 18: 2049, 1999

    Google Scholar 

Download references

Authors
  1. Kim N. Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne E. Wallis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chow Hwee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Lopez de Menezes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jason Sartor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wieslawa H. Dragowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lawrence D. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chi, K.N., Wallis, A.E., Lee, C.H. et al. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 63, 199–212 (2000). https://doi.org/10.1023/A:1017371013487

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1017371013487

Search

Navigation